A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.

NCT02094053 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Down Syndrome

Interventions

DRUG: E2020-Donepezil hydrochloride
DRUG: E2020-Donepezil hydrochloride
DRUG: Placebo

Sponsor

Eisai Co., Ltd.